Non-alcoholic fatty liver disease and diabetes mellitus: targets of metabolic tandem

Cover Page

Cite item

Full Text

Abstract

The prognosis of the World Health Organization indicates that by 2020 non-alcoholic fatty liver disease (NAFLD) will occupy the first position within liver diseases. Liver transplantation in NAFLD patients with cirrhosis occupies second position after viral cirrhosis, nowadays. Mortality in NAFLD patients 1 month after surgery is significantly higher than mortality rate in patients with cirrhosis of different etiology. We also indicate the increased risk of other complications of liver transplantation, such as sepsis, transplant rejection and the development of cardiovascular pathology. According to modern point of view NAFLD is a liver damage, including fatty degeneration, fatty degeneration and inflammatory cell infiltration and injury of hepatocytes (non-alcoholic steatohepatitis/metabolic liver disease) and fibrosis (results in cirrhosis). Cause-effect relation of NAFLD and diabetes mellitus (DM) is the subject of numerous discussions. The connecting pathogenetic link between NAFLD and DM is insulin resistance. The realization of insulin resistance is primarily carried out in hepatocytes. Specific diagnostic criteria for NAFLD practically do not exist; the most likely NAFLD diagnosis is an "exclusion diagnosis". There is no standard therapy for patients with NAFLD, nowadays. None of the drugs used in the treatment of NAFLD has high evidential base. Correction of body-mass index, food addiction and physical activity is the most effective actions to prevent the development of NAFLD and diabetes mellitus.

About the authors

L. A Zvenigorodskaya

Moscow Clinical Science-Research Center of the Department of Health of Moscow

Email: msll@rambler.ru
д-р мед наук, проф. вед. науч. сотр. отд. эндокринных и метаболических нарушений ГБУЗ МКНЦ 111123, Russian Federation, Moscow, sh. Entuziastov, d. 86

M. V Shinkin

Moscow Clinical Science-Research Center of the Department of Health of Moscow

Email: jendis@yandex.ru
мл. науч. сотр. отд. эндокринных и метаболических нарушений 111123, Russian Federation, Moscow, sh. Entuziastov, d. 86

References

  1. Буеверов А.О., Богомолов П.О., Маевская М.В. Патогенетическое лечение неалкогольного стеатогепатита: обоснование, эффективность, безопасность. Терапевт. арх. 2007; 79 (8): 1-4.
  2. Драпкина О.М., Гацолаева Д.С., Ивашкин В.Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. Рос. мед. вести. 2010; 2: 72-8.
  3. Звенигородская Л.А Органы пищеварения и атеросклероз. М.: Медпрактика-М, 2011; с. 149-76.
  4. Ивашкин В.Т. Ядерные рецепторы в патологии печени. Роc. журн. гастроэнтерологии, гепатологии, колопроктологии. 2010; 4: 7-15.
  5. Ивашкин В.Т., Драпкина О.М., Маев И.В. и др. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно - поликлинической практики в РФ: результаты исследования DIREG 2. Роc. журн. гастроэнтерологии, гепатологии, колопроктологии. 2015; 6: 31-41.
  6. European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non - alcoholic fatty liver disease. J Hepatol 2016; 64 (6): 1388-402.
  7. Dajani A, Abu Hammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol 2016; 22 (2): 91-105.
  8. Neuschwander-Tetri B.A, Loomba R, Sanyal A.J et al. Farnesoid X nuclear receptor ligand obeticholic acid for non - cirrhotic, non - alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo - controlled trial. Lancet 2015; 385 (9972): 956-65.
  9. Fang S, Suh J.M, Reilly S.M et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015; 21 (2): 159-65.
  10. Staels B, Rubenstrunk A, Noel B et al. Hepatoprotective effects of the dual peroxisome proliferator - activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2013; 58 (6): 1941-52.
  11. Athyros V.G et al. Safety and efficacy of long - term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post - hoc analysis. Lancet 2010; 376 (9756): 1916-22.
  12. Nozaki Y, Fujita K, Yoneda M et al. Long - term combination therapy of ezetimibe and acarbose for nonalcoholic fatty liver disease. J Hepatol 2009; 51: 548-56.
  13. Park H, Shima T, Yamaguchi K et al. Efficacy of long - term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-7.
  14. Loomba R, Sirlin C.B, Ang B et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015; 61 (4): 1239-50.
  15. Charlton M.R, Burns J.M, Pederson R.A et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-53.
  16. Yalamanchili K, Saadeh S, Klintman G.B et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transplant 2010; 16: 431-9.
  17. Haukeland J.W, Konopski Z, Eggesbo H.B et al. Metformin in patients with nonalcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853-60.
  18. Zhang Z.J, Zheng Z.J, Shi R et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta - analysis. J Clin Endocrinol Metab 2012; 97 (7): 2347-53.
  19. Hussein O et al. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Digestive diseases and sciences 2007; 20. 10: 2512-9.
  20. Sanyal A.J et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2 (12): 1107-15.
  21. Younossi Z.M, Koenig A.B, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease - Meta - analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (1): 73-84.
  22. Solga S.F, Diehl A. Non - alcoholic fatty liver disease: lumen - liver interactions and possible role for probiotics. J Hepatol 2003; 38: 681-7.
  23. Parnell J.A, Raman M, Rioux K.P, Reimer R.A. The potential role of prebiotic fibre for treatment and management of non - alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int 2012; 32: 701-11.
  24. Xiang Z, Chen Y.P, Ma K.F et al. The role of ursodeoxycholic acid in non - alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 2013; 13: 140.
  25. Ratziu V, de Ledinghen V, Oberti F et al. A randomized controlled trial of high - dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54 (5): 1011-19.
  26. Houghton D, Thoma C, Hallsworth K et al. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol 2016; Aug 10 [Epub ahead of print].
  27. Hallsworth K, Fattakova G, Hollingsworth K.G et al. Resistance exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-83.
  28. Fang S, Suh J.M, Reilly S.M et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015; 21 (2): 159-65.
  29. Brunzell J.D, Ayyobi A.F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003; 115 (Suppl. 8A): 24S-28S.
  30. Burt A.D, Mutton A, Day C.P. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagh Pathol 1998; 4: 246-58.
  31. Lewis G.F, Carpentier A, Adeli K et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23 (2): 201-29.
  32. Azzout-Marniche D, Becard D, Guichard C et al. Insulin effects on sterol regulatory - element - binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J 2000; 350: 389-93.
  33. Namikawa C, Shu-Ping Z, Vyselaar J.R et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese su - peroxide dismutase gene in non - alcoholic steatohepatitis. J Hepatol 2004; 40: 781-6.
  34. Loomba R, Lutchman G, Kleiner D.E et al. Clinical trial: pilot study of metformin for the treatment of non - alcoholic. steatohepatitis. Aliment Pharmacol Ther 2009; 29 (2): 172-82.
  35. Haukeland J.W, Konopski Z, Eggesbo H.B et al. Metformin in patients with non - alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44 (7): 853-60.
  36. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009; 46 (2): 113-8.
  37. Lavine J.E, Schwimmer J.B, Molleston J.P et al. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010; 31 (1): 62-70.
  38. Babu A. Canagliflozin for the treatment of type 2 diabetes. Drugs Today (Barc) 2013; 49 (6): 363-76.
  39. Nisly S.A, Kolanczyk D.M, Walton A.M. Canagliflozin, a new sodium - glucose cotransporter 2 inhibitor, in the treatment of diabetes. Am J Health Syst Pharm 2013; 70 (4): 311-19.
  40. INVOKANATM [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; March 2013.
  41. James Toouli, Michael Fried et al. Obesity. World Gastroenterology Organisation Global Guideline. 2009. http://www.worldgastroenterology.org/UserFiles/file/guidelines/obesity-russian-2009.pdf

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies